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Abstract Human lactoferrin contains a 46 residue sequence 
named lactoferricin H thought to be responsible for its 
antimicrobial properties. Synthetic peptides HLTI, correspoml- 
ing to the loop region of human lactoferricin (FQWQR- 
NMRKVRGPPVS) and HLT2, corresponding to its charged 
portion (FQWQRNMRKVR), exerted significant antibacterial 
effects against £. co//serotype O111 strains NCTC 8007 and 
ML35. The corresponding sequences In native human lactoferrin 
were shown to adopt a charged helix and hydrophoble tall within 
the N-lobe remote from the iron binding site. Sequence 
similarities between lactoferricin and dermaseptin and magainins 
suggest that laetoferricin may act as an amphipathie alpha helix. 
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1. Introduction 
Lactoferrin is an iron-binding lycoprotein of the transfer- 
rin family found in the specific granules of neutrophils and in 
secretions including tears, saliva and milk. It is thought to 
exert an antimicrobial effect at these sites [1,2] independent 
of its iron chelating activity [3]. Pepsin digestion of bovine and 
human lactoferrin releases antibacterial peptides named iacto- 
ferricin B and H respectively which may account for this anti- 
microbial activity [4,5]. Lactoferricin is effective against 
Gram-positive and Gram-negative bacteria as well as yeasts 
[6] but its mechanism of action is unknown. 
Human lactoferricin comprises two chains from residues 1- 
46 from the N-terminus of lactoferrin and includes an 18 
residue loop formed by one of two internal disulphide bridges 
[4]. We have synthesised peptides with sequences correspond- 
ing to parts of the loop region, asse,,Jsed their antibacterial 
activity and compared their structures to those of other 
known antimicrobial peptides and to the structure of the 
same sequence in native human apolactoferrin. Throughout 
this report we adopt residue numbers from the currently ac- 
cepted structure for human lactoferrin [7]. Residue numbers 
differ from those in previous publications [4,5] by one residue 
because of the elimination of one arginine residue between 
positions 2 and 4 from the previously published sequence [8]. 
2. Materials and methods 
Lactoferrin was purified to homogeneity, asassessed by SDS poly- 
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acrylamide gel electrophoresis from human milk whey by heparin- 
Sepharose chromatography [9]. Peptide HLTI, corresponding to the 
loop region of human lactoferricin (residues 20-35; NH2- 
FQWQRNMRKVRGPPVS-COOH), was synthesised using Fastmoc 
(Applied Biosystems Inc.) chemistry on an Applied Biosystems 431A 
solid phase peptide synthesizer. The protected peptide was cleaved 
and deprotected using the cleavage mixture phenol/ethanedithiol/ 
water/trifluoroacetic acid and precipitated using diethyl ether. The 
peptide was dried and dissolved in water for reverse phase HPLC 
purification. The product was analysed on a Fisons Instruments VG 
Platform electrospray mass peztror,'~eter. P ptide HLT2, correspond 
ing to the positively charged portioa of the loop region of hun~an 
lactoferricin (residues 24-35; NH2-FQWQRNMRKVR-COOH), 
was synthesised commercially (Neosystem Laboratoire, Strasbourg). 
Peptide HLT5, corresponding to the uncharged portion of the loop 
region (residues 31-35; NH2-GPPVS-COOH), was synthesised using 
Fmoc protection on a Rainin PS3 solid phase peptide synthesiser 
(Protein Technologies Inc. USA) using previously described proce- 
dures [10]. A mixture of two peptides, each containing part of the 
positively charged potentially helical region, was prepared by cyano- 
gen bromide cleavage of peptide HLT1 on the C-terminus of the 
single methionine residue. Purity of peptides was assessed by HPLC 
and mass pectrometry. The effectiveness of HLT! cleavage was con- 
firmed by SDS-PAGE. 
Antibacterial activity was tested against E. coii serotype 0111 
NCTC 8007 and E. coil ML35 [11], a species resistant to the action 
of apo-lactoferrin alone [!]. Suspensions of 10?/ml early log phase 
bacteria, determined spectrophotometrically, were incubated with 
varying concentrations of lactoferrin and peptides in !% proteose 
peptone (Oxoid, Basingstoke, UK) for 2 h at 37°C. Residual viability 
was assessed by serial dilution and drop counting on nutrient agar 
plates. 
The structure of the loop region of iactoferricin H in native human 
apo-lactoferrin was examined using coordinates of the apolactoferrin 
structure [7] and figures were generated using the Evans and Suther- 
land PS390 graphics ystem and FRODO software [12]. Sequences 
were compared for structural similarity by manual alignment of pub- 
lished sequence data for human and bovine lactoferricin [4], derma- 
septin [13] and magainins I and II [14]. 
3. Results 
Peptides HLTI (whole loop) and HLT2 (positively charged 
portion of loop) exhibited potent anti-bacterial activity 
against E. coll. In contrast, native apolactoferrin was inactive 
(Fig. 1) under the same conditions. Both the peptides and the 
cyanogen bromide fragments of HLTI exert a dose dependent 
effect which is equally potent against both strains. There is no 
significant difference between the potency of HLTI and 
HLT2. The cyanogen bromide cleavage products retain sig- 
nifican~ antibacterial ctivity. Peptide HLT5, consisting of the 
uncharged part of the loop, had no activity (Fig. I). Killing by 
HLTI was ~ime dependent and maximal at 90 rain in this 
model although much more rapid effects are detectable by 
other methods (data not shown). 
In native human apolactofen'in the loop region of human 
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Fig. !. Antibacterial ctivity of lactoferdn, peptides and cleavage fragments against E. coil strains 8007 (left) and ML35 (right). Mean viabili- 
ty+standard error derived from a minimum of 4 experiments; lactoferrin (O), HLT! (A), HLT2 (A), HLT5 (v) and cyanogen bromide 
cleaved HLTI (o). 
lactoferricin was found to form an a-helix with a short hydro- 
phobic tail in the N-terminal lobe (Fig. 2). The region corre- 
spondin8 to HLT2 comprises the complete helical portion. 
This helix is exposed on the surface of the molecule away 
from the iron binding site with its four ba.fic residue side 
chains extending outwards (Fig. 3). 
A similarity is revealed between the primary structure of 
various lactoferrins, human and bovine lactoferricins and der- 
maseptin and magainins, antibacterial peptides from frog and 
toad respectively. This is enhanced by including insertions and 
extending the sequences beyond the antimicrobial segments 
(Table I), 
4. Digtmlen 
Two larger peptides corresponding to residues 17-39 of hu- 
man lactoferricin and residues 17-41 from bovine lactoferricin 
have previously been shown to be antibacterial [4]. The hu- 
man peptide comprises two peptide chains linked by a disul- 
phide bridge. Antibacterial ctivity is known to be independ- 
ent of a second isulphide bridge which closes the loop region. 
We have shown that a much smaller 11 residue peptide 
(HLT2) homologous to just over half the loop region has 
potent antibacterial ctivity and may account for all the ac- 
tivity of the larger HLT! peptide. HLTI contains four posi- 
tively charged residues and charge is likely to be an important 
activity determinant because the antibacterial ctivity of lac- 
toferrin [!,15] and lactoferricin [5,16] is probably dependent 
on binding to the bacterial surface. The potency of the killing 
is slightly less than has been reported previously for the larger 
human and bovine peptide in a different antibacterial ssay 
system [4]. It is not clear whether this might be due to differ- 
ences in the target organism, peptide purity, the target : pep. 
tide stoichiometry or to the sequences themselves. No anti- 
bacterial effect of intact apo-lactoferrin against E. coil was 
demonstrated in our assay system and this is in keeping 
with previous work indicating that lactoferrin has either no 
effect [1] or at best a bacteriostatic effect [17] against E. coil 
Table I 
Sequence alignment ofantimicrobial peptides with lactoferrins including regions beyond the antimic:obial segments 
Peptide Sequence Reference 
~rmamptinl ALWKTMLKKL-GTMALHA~KAALGA. . .  [18] 
Malga in in l  mVRGIGg~LHSAGEF-GKAFVGEXHKSKRD. . .  [14] 
Magaininl[ EV~GIGEFLHSAEEF-GKAFVGEIMNSKRD. . .  [14] 
~vinelacto~rrin EWFKCRRWQWRMKKL-GAPS ITCV .... RR&F. .  [32] 
Mou~lacto~mn gEEKCLRWQNEMRKV-G-PPVSCI - - -KKS . . .  [31] 
Human l~to~n BATKCF~WQRNMRgVRG-PPVSCL- - -KRD [7] 
Peptide HLTI 
Peptide HLT2 
FQWQRNMRKVRGPPVS 
FQWQRNMRKVR 
Residues in bold are homologous between one or more lactoferrin sequenc~ and one or more antibacterial sequence. Homologies within each 
{group are not highlighted. Underlined sequences represent bovine lactoferricin and the longer peptide chain uf human lactoferricin which con- 
rains the loop region. Peptides HLTI and HLT2, homologous tohuman iactoferrin, are also shown. 
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Fig. 2. 3-D structure of human apolactoferrin with the loop region of lactoferricin (in the N-lobe, 3 turn helix) ana a homologous sequence ~m 
the C-lobe, 2 turn helix) highlighted. N-lobes upper, two views rotated 900 on a vertical axis. The C-lobes are closed. Co.ordinates from Ander- 
son et al. [7]. 
Cleavage of HLTI with cyanogen bromide yields two pep- 
tides each with a positive charge and an aromatic terminal 
residue. The finding that these fragments retained antibacter- 
ial activity similar to an ,~,~uimolar concentration of HLTI is 
intriguing and it is not clea, whether one or both products 
might account for the activity. Other peptides based on these 
cleavage products will be investigated in future work. 
It would appear significant that the loop region can adopt a 
helical conformation i  apo.lactoferrin as this is a feature of 
some antibacterial peptides. An amphipathic a.helical 18 res- 
idue region at the amino terminus of dermaseptin [18] and 
synthetic homologous peptides [19] appears to be responsible 
for their antibacterial ctivity. Magainins also adopt a helical 
structure [20] and are thought o act by forming a tetrameric 
pore in which the helix lies parallel to the target membrane 
[21]. Cecropins have a similar hinged helical structure [22] and 
may also rely on polymer formation for their action [23]. All 
share the ability to form anion pores and all have a wide 
spectrum of antibacterial ctivity [24]. CAPI~; [25] and hista- 
tin [26] are also partly a-helical. Some, like lactoferricin and 
HLTI, have their charged residues on one side of the helix 
and it is their helical nature rather than their chirality which is 
critical [27,28]. Monomeric HLT2 appears too short to span a 
bacterial membrane although other synthetic amphipathic a- 
helical peptides as short as 9 [29] and 15 [30] residues retain 
bactericidal ctivity. However, it is possible that these shorter 
peptides have a different mechanism of action [29,30]. There is 
no experimental evidence to suggest hat HLT1 or HLT2 
form helical structures in free aqueous olution and this seems 
unlikely given their short length. 
Further evidence of similarity between these peptides and 
helical antibacterial peptides i suggested by alignment of their 
primary sequences. Previously it has been considered that no 
similarity exists beyond the density of positively charged resi-' 
dues [4]. Similar types of amino acid occur in equivalent posi~ 
tions and these partial homologies will be exploited in the 
design of peptides for further work. The actual 3D structure 
of lactoferricin derived peptides remains to be elucidated. De- 
termination of solution structure has not yet been attempted 
because similar short peptides are known to adopt heir helical 
conformation only when bound to membre, nes [20]. 
We have observed that the loop region of human lactofer- 
ricin forms a charged o~-helix on the surface of lactoferrin in a 
site remote from the iron binding site. Peptides homologous 
to the charged helical portion of the peptide xert anti-bacter- 
ial activity in vitro and their action may be related to that of 
other antibacterial peptides of the amphipathic alpha helix 
family. Further work is in progress to characterise their me- 
chanism of action using peptides designed in the light of our 
reported sequence similarities. 
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Fig. 3, Ribbon model of lactoferricin showing the helical conforma- 
tion adopted in native human apolactoferrin. The charged arginine 
and lysine side chains are clustered on one side of the helix. Note 
the comments on residue numbering in ~cction I.
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